Pozen Seeks FDA Approval for Migraine Drug
Posted on: Monday, 8 August 2005, 18:01 CDT
Aug. 8--Pozen launched its third attempt to win regulatory approval for an experimental migraine drug.
Following two rejections, for experimental treatments known as MT100 and MT300, the Chapel Hill drug development company said Monday that it submitted MT400 for approval with the Food and Drug Administration. The experimental drug's proposed brand name is Trexima.
GlaxoSmithKline has the rights to market and manufacture Trexima. The British pharmaceutical giant, which has a U.S. headquarters in Research Triangle Park and employs about 6,000 in the Triangle, has agreed to pay Pozen $20 million once the FDA accepts the regulatory filing.
-----
To see more of The News & Observer, or to subscribe to the newspaper, go to http://www.newsobserver.com.
Copyright (c) 2005, The News & Observer, Raleigh, N.C.
Distributed by Knight Ridder/Tribune Business News.
For information on republishing this content, contact us at (800) 661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-6515, or e-mail reprints@krtinfo.com.
POZN, GSK,
Source: The News & Observer
Related Articles
- Breaking the News, or Fueling the Epidemic? News Coverage of Opioid-Related Deaths Often Precede an Increase in Deaths, Study Finds
- Cocaine Exposure During Pregnancy Leads To Impulsivity In Male, Not Female, Monkeys
- Athletes Use Viagra for a Competitive Edge, Experts Say
- Land of the Living Sky With Diamonds: A Place for Radical Psychiatry?
- NIDA Chief Studies the Brains of Addicts
- NIDA Chief Studies the Brain of Addicts
- PROFNET WIRE: EDUCATION & SCIENCE: Military Recruiting on Campus
- Who's Fighting Cancer in Kids?
- Medieval Fictional Odysseys: Better Time Travel Through Hallucinogens, Nets, and Quantum Foam
- A Review of Multi-Threat Medical Countermeasures Against Chemical Warfare and Terrorism
 |
 |
User Comments (0)
RSS Feeds